GILEAD SCIENCES, INC. Revenue
GILEAD SCIENCES, INC. (GILD) reported Revenue of $7.80 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $7.80B, a 10.18% increase year-over-year.
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $6.96B, a 4.39% increase year-over-year.
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $7.92B, a 4.70% increase year-over-year.
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $7.77B, a 2.97% increase year-over-year.
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $29.44B, a 2.40% increase from fiscal 2024.
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $28.75B, a 6.04% increase from fiscal 2023.
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $27.12B, a 0.60% decline from fiscal 2022.
- GILEAD SCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $27.28B, a 0.09% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.80B 10-Q · filed 2026-08-06 | $14.76B 10-Q · filed 2026-08-06 | $22.69B derived: sum of 3 quarters · filed 2026-08-06 | $30.46B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.96B 10-Q · filed 2026-05-07 | $14.88B derived: sum of 2 quarters · filed 2026-05-07 | $22.65B derived: sum of 3 quarters · filed 2026-05-07 | $29.74B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.92B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $15.69B derived: sum of 2 quarters · filed 2026-02-24 | $22.78B derived: sum of 3 quarters · filed 2026-08-06 | $29.44B 10-K · filed 2026-02-24 |
| 2025-09-30 | $7.77B 10-Q · filed 2025-11-07 | $14.85B derived: sum of 2 quarters · filed 2026-08-06 | $21.52B 10-Q · filed 2025-11-07 | $29.09B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.08B 10-Q · filed 2026-08-06 | $13.75B 10-Q · filed 2026-08-06 | $21.32B derived: sum of 3 quarters · filed 2026-08-06 | $28.86B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.67B 10-Q · filed 2026-05-07 | $14.24B derived: sum of 2 quarters · filed 2026-05-07 | $21.78B derived: sum of 3 quarters · filed 2026-05-07 | $28.73B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.57B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $15.11B derived: sum of 2 quarters · filed 2026-02-24 | $22.07B derived: sum of 3 quarters · filed 2026-02-24 | $28.75B 10-K · filed 2026-02-24 |
| 2024-09-30 | $7.54B 10-Q · filed 2025-11-07 | $14.50B derived: sum of 2 quarters · filed 2025-11-07 | $21.18B 10-Q · filed 2025-11-07 | $28.30B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $6.95B 10-Q · filed 2025-08-07 | $13.64B 10-Q · filed 2025-08-07 | $20.75B derived: sum of 3 quarters · filed 2026-02-24 | $27.80B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $6.69B 10-Q · filed 2025-05-07 | $13.80B derived: sum of 2 quarters · filed 2026-02-24 | $20.85B derived: sum of 3 quarters · filed 2026-02-24 | $27.45B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $7.11B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $14.16B derived: sum of 2 quarters · filed 2026-02-24 | $20.76B derived: sum of 3 quarters · filed 2026-02-24 | $27.12B 10-K · filed 2026-02-24 |
| 2023-09-30 | $7.05B 10-Q · filed 2024-11-12 | $13.65B derived: sum of 2 quarters · filed 2024-11-12 | $20.00B 10-Q · filed 2024-11-12 | $27.39B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $6.60B 10-Q · filed 2024-08-08 | $12.95B 10-Q · filed 2024-08-08 | $20.34B derived: sum of 3 quarters · filed 2025-02-28 | $27.38B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $6.35B 10-Q · filed 2024-05-08 | $13.74B derived: sum of 2 quarters · filed 2025-02-28 | $20.78B derived: sum of 3 quarters · filed 2025-02-28 | $27.04B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $7.39B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $14.43B derived: sum of 2 quarters · filed 2025-02-28 | $20.69B derived: sum of 3 quarters · filed 2025-02-28 | $27.28B 10-K · filed 2025-02-28 |
| 2022-09-30 | $7.04B 10-Q · filed 2023-11-07 | $13.30B derived: sum of 2 quarters · filed 2023-11-07 | $19.89B 10-Q · filed 2023-11-07 | $27.14B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $6.26B 10-Q · filed 2023-08-04 | $12.85B 10-Q · filed 2023-08-04 | $20.09B derived: sum of 3 quarters · filed 2024-02-23 | $27.52B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $6.59B 10-Q · filed 2023-05-03 | $13.83B derived: sum of 2 quarters · filed 2024-02-23 | $21.25B derived: sum of 3 quarters · filed 2024-02-23 | $27.47B derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $7.24B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $14.66B derived: sum of 2 quarters · filed 2024-02-23 | $20.88B derived: sum of 3 quarters · filed 2024-02-23 | $27.30B 10-K · filed 2024-02-23 |
| 2021-09-30 | $7.42B 10-Q · filed 2022-11-02 | $13.64B derived: sum of 2 quarters · filed 2022-11-02 | $20.06B 10-Q · filed 2022-11-02 | $27.48B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $6.22B 10-Q · filed 2022-08-08 | $12.64B 10-Q · filed 2022-08-08 | $20.06B derived: sum of 3 quarters · filed 2023-02-22 | $26.64B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $6.42B 10-Q · filed 2022-05-04 | $13.84B derived: sum of 2 quarters · filed 2023-02-22 | $20.42B derived: sum of 3 quarters · filed 2023-02-22 | $25.56B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $7.42B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $14.00B derived: sum of 2 quarters · filed 2023-02-22 | $19.14B derived: sum of 3 quarters · filed 2023-02-22 | $24.69B 10-K · filed 2023-02-22 |
| 2020-09-30 | $6.58B 10-Q · filed 2021-11-03 | $11.72B derived: sum of 2 quarters · filed 2021-11-03 | $17.27B 10-Q · filed 2021-11-03 | $23.15B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $5.14B 10-Q · filed 2021-08-05 | $10.69B 10-Q · filed 2021-08-05 | $16.57B derived: sum of 3 quarters · filed 2022-02-23 | $22.17B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $5.55B 10-Q · filed 2021-05-06 | $11.43B derived: sum of 2 quarters · filed 2022-02-23 | $17.03B derived: sum of 3 quarters · filed 2022-02-23 | $22.72B derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $5.88B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $11.48B derived: sum of 2 quarters · filed 2022-02-23 | $17.17B derived: sum of 3 quarters · filed 2022-02-23 | $22.45B 10-K · filed 2022-02-23 |
| 2019-09-30 | $5.60B 10-Q · filed 2019-11-05 | $11.29B derived: sum of 2 quarters · filed 2019-11-05 | $16.57B 10-Q · filed 2019-11-05 | $22.36B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $5.68B 10-Q · filed 2019-08-06 | $10.97B 10-Q · filed 2019-08-06 | $16.76B derived: sum of 3 quarters · filed 2021-02-25 | $22.36B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $5.28B 10-Q · filed 2019-05-08 | $11.08B derived: sum of 2 quarters · filed 2021-02-25 | $16.67B derived: sum of 3 quarters · filed 2021-02-25 | $22.32B derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $5.79B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $11.39B derived: sum of 2 quarters · filed 2021-02-25 | $17.04B derived: sum of 3 quarters · filed 2021-02-25 | $22.13B 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.60B 10-Q · filed 2019-11-05 | $11.24B derived: sum of 2 quarters · filed 2019-11-05 | $16.33B 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $5.65B 10-Q · filed 2019-08-06 | $10.74B 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $5.09B 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $26.11B 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $30.39B 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |